标题
KALRN mutations promote antitumor immunity and immunotherapy response in cancer
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000293
出版商
BMJ
发表日期
2020-10-10
DOI
10.1136/jitc-2019-000293
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Evolution of the Rho guanine nucleotide exchange factors Kalirin and Trio and their gene expression in Xenopus development
- (2019) Marie-Claire Kratzer et al. GENE EXPRESSION PATTERNS
- ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
- (2019) Lin Li et al. Cells
- Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature
- (2018) Christian Grønhøj et al. BMC CANCER
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
- (2018) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
- (2017) Federica Zito Marino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
- (2017) Yoshihiko Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response
- (2016) Guillaume Sarrabayrouse et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Regulating Rho GTPases and their regulators
- (2016) Richard G. Hodge et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
- (2014) J. Xia et al. MOLECULAR CANCER THERAPEUTICS
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Melanoma Cells Treated with GGTI and IFN-γ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells
- (2010) Guillaume Sarrabayrouse et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now